Learn Before
Findings opposed to use of Azithromycin+Hydroxychloroquine as COVID-19 intervention
Findings about use of Azithromycin as COVID-19 intervention from study of hospitalized patients in New York City
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
Proportion of abnormal ECG findings in hospitalized COVID-19 patients in New York City were higher amongst those who received Azithromycin+Hydroxychloroquine and Hydroxychloroquine
"A greater proportion of patients receiving hydroxychloroquine + azithromycin experienced cardiac arrest (15.5%) and abnormal ECG findings (27.1%), as did those in the hydroxychloroquine alone group (13.7% and 27.3, respectively), compared with azithromycin alone (6.2% and 16.1%, respectively) and neither drug (6.8% and 14.0%, respectively)."
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Hazard ratio for time to in-hospital mortality amongst hospitalized COVID-19 patients in New York City were not significantly different for those given Azithromycin, Hydroxychloroquine, or a combination
Proportion of abnormal ECG findings in hospitalized COVID-19 patients in New York City were higher amongst those who received Azithromycin+Hydroxychloroquine and Hydroxychloroquine
Hazard ratios for ventricular arrhythmia among COVID-19 patients given different antimalarial and macrolide therapies from multinational registry of patients hospitalized between 12/20/19 and 4/14/20
Hazard ratios for in-hospital mortality among COVID-19 patients given different antimalarial and macrolide therapies from multinational registry of patients hospitalized between 12/20/19 and 4/14/20
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
Findings from a Systematic Review and Meta-Analysis on the Effect of Hydroxychloroquine With or Without Azithromycin on the Mortality of COVID-19 Patients
Hazard ratio for time to in-hospital mortality amongst hospitalized COVID-19 patients in New York City were not significantly different for those given Azithromycin, Hydroxychloroquine, or a combination
Proportion of abnormal ECG findings in hospitalized COVID-19 patients in New York City were higher amongst those who received Azithromycin+Hydroxychloroquine and Hydroxychloroquine
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
Methods for determining odds of cardiac arrest amongst hospitalized COVID-19 patients in New York City given Azithromycin, Hydroxychloroquine, or a combination
Hazard ratio for time to in-hospital mortality amongst hospitalized COVID-19 patients in New York City were not significantly different for those given Azithromycin, Hydroxychloroquine, or a combination
Proportion of abnormal ECG findings in hospitalized COVID-19 patients in New York City were higher amongst those who received Azithromycin+Hydroxychloroquine and Hydroxychloroquine